Through the new DTP platform, Novartis will make Cosentyx available to patients at a price that reflects the average savings typically retained by insurers and pharmacy benefit managers
The expansion will significantly enhance AbbVie’s ability to meet growing global demand for biologics, particularly in oncology and immunology
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment
The platform integrates artificial intelligence into a unified environment that supports optical, microCT, ultrasound, and other imaging modalities
Sanofi Ventures drives innovation through leading and participating in private financing rounds for pioneering healthcare companies
Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs
82,514 sq ft facility to host up to 15 biotech companies, fueling the development of next-generation medicines
Subscribe To Our Newsletter & Stay Updated
